LSL Pharma Group

LSL Pharma Group announces a change in its chief financial officer.

The company seeks talent for careers across its subsidiaries.

The page lists the members of the board of directors.

The page provides board of directors information, investor resources, financial reports, and news.

Laboratoire LSL develops and contract-manufactures natural health products, while Steri-Med Pharma produces sterile ophthalmic products.

The page provides email and phone contact details for administrative offices.

The company invests in life sciences innovation to support healthy living for Canadians.

LSL Pharma Group Inc. presents at the **Planet MicroCap Toronto 2026** conference on October 28. The company, listed on the TSX Venture Exchange, will showcase its operations as an integrated Canadian pharmaceutical business. François Roberge, President & CEO, leads the presentation and takes questions from attendees.

Oct 2026newswire.caNews article

Research Capital Corporation begins equity research coverage of **LSL Pharma Group**, a Canadian pharmaceutical company. This marks the first independent analyst report on the firm, published by Research Capital. The move highlights growing institutional interest in LSL Pharma’s integrated drug development and manufacturing operations.

Oct 2026newswire.caNews article

LSL Pharma Group replaces its Chief Financial Officer as Luc Mainville departs the role immediately. The company operates as an integrated pharmaceutical business listed on the TSX Venture Exchange. No successor has been named in the announcement.

Sep 2026newswire.caNews article

LSL Pharma Group reports record revenues for the second quarter of 2026, marking its strongest financial performance to date. The Canadian pharmaceutical company highlights growth in its integrated operations, though specific figures or details on drivers are not disclosed. The results cover the period ending June 30, 2026, with all financial figures presented in millions of Canadian dollars.

Aug 2026newswire.caNews article